Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Orderly Meds and Mochi both operate as telehealth platforms connecting patients with licensed providers for compounded GLP-1 peptide access. Orderly Meds focuses on streamlined prescription workflows and pharmacy coordination, while Mochi emphasizes provider-led clinical assessment and longitudinal care models. Both serve the growing demand for accessible weight-loss and metabolic medications outside traditional clinic settings.
Choosing between these platforms requires understanding their clinical philosophies, cost structures, and how each integrates provider oversight. PlexusDx supports precision-based decision-making by offering Precision Peptide Genetic Testing alongside compounded options, enabling patients and providers to make informed choices regardless of which telehealth channel they ultimately use.
Orderly Meds Platform Model and Clinical Framework
Orderly Meds operates a direct-to-pharmacy model, where licensed providers evaluate patient histories remotely and authorize compounded prescriptions. The platform emphasizes efficiency in the approval-to-dispensing pipeline, allowing patients to receive semaglutide or tirzepatide compounds within days. Orderly Meds providers follow evidence-based screening for cardiovascular history, kidney function, and weight-loss goals.
The Orderly Meds clinical framework typically includes baseline labs (optional for some tiers), provider consultation via text or video, and coordination with licensed 503A compounding pharmacies. Their model appeals to patients prioritizing speed and straightforward access. However, ongoing monitoring frequency varies by provider assignment, which may influence clinical outcomes tracking.
Mochi Telehealth: Comprehensive Provider-Led Assessment
Mochi positions itself around comprehensive medical evaluation, requiring detailed patient intake and structured follow-up visits. Providers on the Mochi network conduct behavioral assessment, review medication interactions, and establish baseline metabolic markers before initiating compounded GLP-1 therapy. This model aligns with clinical guidelines emphasizing longitudinal provider-patient relationships in peptide prescribing.
Mochi's strength lies in sustained accountability—patients receive scheduled check-ins, dose-titration guidance, and side-effect management support. Compounding pharmacy coordination is handled within the Mochi system, streamlining fulfillment. The trade-off is typically longer initial approval timelines and higher consultation costs compared to transaction-based models.
Side-by-Side Platform Comparison Framework
Understanding how Orderly Meds and Mochi differ across key clinical and operational dimensions helps align patient needs with platform strengths. The table below outlines factors that may influence your choice between these two telehealth pathways for accessing compounded peptides.
| Dimension |
Orderly Meds |
Mochi |
| Initial Approval Timeline |
2–5 days typical |
3–7 days with intake assessment |
| Provider Continuity Model |
Assigned or rotating providers |
Dedicated long-term provider |
| Ongoing Visit Frequency |
As-needed or quarterly |
Structured monthly or bi-weekly |
| Baseline Lab Requirements |
Flexible (optional tiers) |
Usually required before initiation |
| Compounding Pharmacy Integration |
Direct coordination |
In-network pharmacy system |
| Cost per Consult |
$50–150 range |
$100–200+ per visit |
| Side-Effect Support |
Text/chat available |
Scheduled clinical visits |
| Medication Options |
Semaglutide, tirzepatide compounds |
Semaglutide, tirzepatide compounds |
Clinical Evidence Guiding Provider Selection Between Platforms
Research on GLP-1 prescribing emphasizes that provider oversight, regular monitoring, and dose titration reduce side-effect discontinuation rates. Both Orderly Meds and Mochi support these principles, but operationalize them differently. Orderly Meds suits stable patients with clear risk profiles; Mochi serves those requiring intensive behavioral and metabolic coaching during initiation.
Clinical guidelines from endocrinology societies recommend baseline cardiovascular assessment, kidney function testing, and family history evaluation before GLP-1 use. Mochi's mandatory assessment structure aligns closely with these recommendations, while Orderly Meds' flexible approach enables faster access for low-risk patients. Neither platform negates the need for baseline evaluation—rather, they differ in how thoroughly and quickly they complete it.
Safety, Eligibility Criteria, and Informed Decision-Making
Both platforms screen for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe kidney impairment. Orderly Meds and Mochi require honest disclosure of medical history; neither can substitute for a thorough patient-provider conversation. Compounded peptides carry the same safety profile as branded GLP-1 medications when produced in licensed 503A pharmacies.
Eligibility should be evaluated with your chosen platform's provider and supported by baseline labs. PlexusDx's Precision Peptide Genetic Test may help provide additional context around your genetic predispositions in key GLP-1 receptor and metabolic pathways, supporting a more informed conversation with your Orderly Meds or Mochi provider about personalized dosing and response expectations.
How PlexusDx Supports a More Personalized Approach
Genetic variants in GLP1R, GIPR, FTO, and MC4R pathways influence how individuals metabolize peptide drugs and respond to weight-loss interventions. While neither Orderly Meds nor Mochi routinely incorporates genetic testing into their intake, understanding your genetic predispositions may help guide conversations with your assigned provider about optimal dosing strategies and realistic outcome timelines.
PlexusDx's Precision Peptide Genetic Test reveals your predispositions in key peptide-receptor and metabolic pathways—specifically variants in GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. This test does not predict exact medication response but may help provide context to support a more personalized conversation with your provider, whether you choose Orderly Meds, Mochi, or another telehealth platform.
If you pursue compounded GLP-1 therapy through either platform, consider pairing your provider consultation with the Precision Peptide Genetic Test. This combination enables your provider to discuss potential response patterns, realistic dose ranges, and monitoring schedules tailored to your genetic profile—moving beyond one-size-fits-all prescribing toward precision-informed peptide therapy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the main difference between Orderly Meds and Mochi for GLP-1 access?
Orderly Meds emphasizes rapid approval and flexible monitoring, while Mochi prioritizes comprehensive provider assessment and structured follow-up visits. Both use licensed 503A compounding pharmacies; the difference lies in clinical intensity and timeline.
Does Orderly Meds or Mochi cover genetic testing for peptide response?
Neither platform routinely includes genetic testing in their standard assessment. However, PlexusDx offers Precision Peptide Genetic Testing as an add-on or standalone service to support personalized conversations with your provider about your GLP-1 pathway predispositions.
Which platform is faster: Orderly Meds or Mochi?
Orderly Meds typically approves prescriptions in 2–5 days, while Mochi's comprehensive intake process usually takes 3–7 days. Speed depends on your readiness to complete intake and lab requirements.
Are Orderly Meds and Mochi compounded medications as safe as branded GLP-1 drugs?
Compounded semaglutide and tirzepatide from licensed 503A pharmacies carry equivalent safety profiles to branded versions when produced under stringent quality controls. Both platforms coordinate with accredited pharmacies, though final safety depends on ongoing provider monitoring.
Can I use Precision Peptide Genetic Testing with Orderly Meds or Mochi?
Yes. PlexusDx's Precision Peptide Genetic Test is independent of your telehealth platform choice. Results can support conversations with your Orderly Meds or Mochi provider about personalized dosing strategies and metabolic pathway context.
How do Orderly Meds and Mochi differ in cost?
Orderly Meds typically charges $50–150 per consultation, while Mochi ranges $100–200+ per visit. Medication costs are similar across platforms; the difference reflects consultation model intensity and ongoing support structure.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Ro vs Fridays: Telehealth Platform Selection for GLP-1 Peptide Therapy
Zealthy Cost: Compounded GLP-1 Pricing, Genetic Factors, and Personalization